Discover
DRTS
Alpha Tau Medical Ltd.
12.64
2 x 9.19
2 x 15.92
bid
ask
+
0.06
0.48%
2 @ 05:13 AM
12.75 +0.11 (0.87%)
| Ytd | 155.35% | |
| 1y | 305.13% |
12.26
day range
13.06
2.87
52 week range
13.06
| Open | 12.51 | Prev Close | 12.58 | Low | 12.26 | High | 13.06 | Mkt Cap | 1.14B |
| Vol | 1.10M | Avg Vol | 805.69K | EPS | -0.67 | P/E | N/A | Forward P/E | -24.44 |
| Beta | 1.20 | Short Ratio | 1.98 | Inst. Own | 4.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 9.57 | 200-d Avg | 6.62 | 1yr Est | 14.20 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-19 | 2024-09 | -0.13 | -0.1 | 0.03 | 23.08% |
| 2024-08-14 | 2024-06 | -0.13 | N/A | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.13 | -0.11 | 0.02 | 15.38% |
| 2024-05-20 | 2024-03 | -0.13 | -0.11 | 0.02 | 15.38% |
| 2024-05-20 | 2024-03 | -0.13 | N/A | N/A | N/A |
| 2024-03-07 | 2023-12 | -0.13 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | Barclays | Upgrade | Overweight | Overweight |
| 2026-06-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-28 | Barclays | Upgrade | Overweight | |
| 2026-05-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-19 | Piper Sandler | Upgrade | Neutral | Neutral |
Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-24 | LEVY RAPHI | Chief Financial Officer | 110.18K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | HighTower Advisors, LLC | 874.99K | 11.06M | 1.26% |
| 2026-03-30 | Aquamarine Financial (cayman) Ltd | 721.50K | 9.12M | 1.04% |
| 2026-03-30 | Apella Capital, LLC | 382.28K | 4.83M | 0.55% |
| 2026-03-30 | ARK Investment Management, LLC | 292.13K | 3.69M | 0.42% |
| 2026-03-30 | UBS Group AG | 286.69K | 3.62M | 0.41% |
| 2026-03-30 | Daytona Street Capital LLC | 146.11K | 1.85M | 0.21% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | ARK ETF Trust-ARK Israel Innovative Technology ETF | 277.09K | 3.50M | 0.40% |
| 2026-05-30 | RBB Fund, Inc.-Adara Smaller Companies Fund | 83.09K | 1.05M | 0.12% |
| 2026-04-29 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 53.40K | 674.96K | 0.08% |
| 2026-03-30 | Tidal Trust II-Even Herd Long Short ETF | 25.09K | 317.18K | 0.04% |
| 2026-04-29 | Dunham Funds-Dunham Small Cap Growth Fund | 27.11K | 342.68K | 0.04% |